Business Milestones
2025.05.19
TAHO Pharmaceuticals Secures Singapore Patent for TAH3311 Apixaban Anticoagulant Oral Dissolving Film
Taipei — May 19, 2025 – TAHO Pharmaceuticals announced that the Singapore Patent Office has granted its patent application for "Apixaban Film Product and Uses Thereof." This patent protects an innovative film-based formulation of Apixaban, an anticoagulant used to prevent and treat blood clots, reinforcing TAHO’s leadership in advancing drug delivery technologies to improve patient care and accessibility.
The patented Apixaban oral dissolving film leverages cutting-edge transmucosal delivery technology, offering a more convenient alternative to traditional anticoagulant tablets. Patients simply place the film in their mouth, where it dissolves rapidly without the need for water. This solution is designed for individuals with swallowing difficulties, such as stroke survivors, the elderly, and children, enhancing medication adherence while easing the burden on caregivers.
About TAH3311
TAH3311, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s proprietary Transepithelial Delivery System (TDS), TAH3311 dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills.
Proven bioequivalent to Eliquis ® in pivotal clinical studies, TAH3311 is prepared for regulatory submissions to the FDA and EMA. With millions of patients requiring blood thinners annually—and over $26 billion spent in the U.S. alone (Source: IQVIA)—TAH3311 aims to deliver simpler, more compassionate care worldwide.
The patented Apixaban oral dissolving film leverages cutting-edge transmucosal delivery technology, offering a more convenient alternative to traditional anticoagulant tablets. Patients simply place the film in their mouth, where it dissolves rapidly without the need for water. This solution is designed for individuals with swallowing difficulties, such as stroke survivors, the elderly, and children, enhancing medication adherence while easing the burden on caregivers.
About TAH3311
TAH3311, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s proprietary Transepithelial Delivery System (TDS), TAH3311 dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills.
Proven bioequivalent to Eliquis ® in pivotal clinical studies, TAH3311 is prepared for regulatory submissions to the FDA and EMA. With millions of patients requiring blood thinners annually—and over $26 billion spent in the U.S. alone (Source: IQVIA)—TAH3311 aims to deliver simpler, more compassionate care worldwide.